RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma
Titel:
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma
Auteur:
Ravaud, A. Barrios, C.H. Alekseev, B. Tay, M.-H. Agarwala, S.S. Yalcin, S. Lin, C.-C. Roman, L. Shkolnik, M. Anak, O. Gogov, S. Pelov, D. Louveau, A.-L. Melichar, B.